**Health Economics Outcomes Research**

**Publications**

**Journal Articles**


Conference abstracts


11. Cartwright T, Parisi M, Espirito JL, et al: Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma. Presented at the ASCO, Chicago, IL, June 2-6, 2017


30. Kumar SK, Engebretson AE, Baudi FK, et al: Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Presented at the Association for Value-Based Cancer Care Los Angeles, CA, May 6-9, 2014
40. Kumar SK, Engebretson AE, Baudi FK, et al: Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial


